Precision Diagnostics SQI Diagnostics focuses on rapid diagnostic testing across organ transplant, autoimmune disease, and COVID-19, presenting sales opportunities with healthcare providers, transplant centers, and point-of-care settings seeking fast, accurate triage and monitoring tools.

Early Funding Momentum With recent $2 million FedDev Ontario support and financing rounds, there is demonstrated governmental backing and a manufacturing scale-up pathway, suggesting sales angles around scalable production agreements and contract manufacturing for growing demand.

Regulatory Milestones Health Canada interim order authorization for RALI-Dx IL-6 and ongoing development of TORdx LUNG indicate the company’s progress toward broader regulatory approval, creating opportunities to engage hospitals and clinics seeking compliant, ready-to-deploy diagnostics.

Expansion Readiness Funding and partnerships aimed at manufacturing scale-up imply capacity to handle increased volume; target enterprise accounts and regional distributors with needs for reliable supply, copayment-friendly testing, and rapid replenishment.

Diverse Portfolio A multi-product pipeline including direct-to-consumer COVID-19 tests, severity triage tests, and broader respiratory/immune diagnostics opens doors across consumer health channels, urgent care clinics, and specialty laboratories seeking integrated testing solutions.